{"id":70195,"date":"2026-07-17T22:42:45","date_gmt":"2026-07-17T14:42:45","guid":{"rendered":"https:\/\/flcube.com\/?p=70195"},"modified":"2026-07-17T22:42:46","modified_gmt":"2026-07-17T14:42:46","slug":"cspc-pharmaceutical-launches-phase-iii-trial-of-b7-h3-targeting-adc-sys-6043-for-platinum-resistant-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70195","title":{"rendered":"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1093:HKG\">HKG: 1093<\/a>) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating <strong>SYS 6043<\/strong>, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator&#8217;s choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-milestone\" class=\"wp-block-heading\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>CSPC Pharmaceutical Group (HKG: 1093)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SYS 6043<\/td><\/tr><tr><td><strong>Trial Phase<\/strong><\/td><td>Phase III<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer<\/td><\/tr><tr><td><strong>Trial Design<\/strong><\/td><td>Randomized, multi-center, open-label<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Investigator&#8217;s choice of chemotherapy<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-innovation\" class=\"wp-block-heading\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> B7-H3-targeting antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Payload:<\/strong> Topoisomerase I inhibitor<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Engineered to reduce lymphocyte uptake and mitigate off-target toxicity<\/li>\n\n\n\n<li><strong>Safety Advantage:<\/strong> Improved treatment safety profile compared to conventional ADCs<\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> B7-H3 overexpressed in multiple solid tumors including gynecological malignancies<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Protected by composition-of-matter and method-of-use patents<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-phase-i-clinical-data-summary\" class=\"wp-block-heading\">Phase I Clinical Data Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Aspect<\/th><th>Results<\/th><\/tr><\/thead><tbody><tr><td><strong>Tumor Types Evaluated<\/strong><\/td><td>Lung cancer, gynecological malignancies, breast cancer, nasopharyngeal carcinoma<\/td><\/tr><tr><td><strong>Antitumor Activity<\/strong><\/td><td>Promising activity across multiple tumor types<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Generally manageable tolerability<\/td><\/tr><tr><td><strong>Dose Optimization<\/strong><\/td><td>Recommended Phase II\/III dose established<\/td><\/tr><tr><td><strong>Biomarker Analysis<\/strong><\/td><td>Correlation between B7-H3 expression and response observed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-disease-context-amp-unmet-need\" class=\"wp-block-heading\">Disease Context &amp; Unmet Need<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platinum-Resistant Ovarian Cancer:<\/strong> Affects approximately 70% of advanced ovarian cancer patients within 2 years of initial treatment<\/li>\n\n\n\n<li><strong>Treatment Challenge:<\/strong> Limited effective options with median overall survival of 12-15 months<\/li>\n\n\n\n<li><strong>Current Standard:<\/strong> Single-agent chemotherapy with modest response rates (10-15%)<\/li>\n\n\n\n<li><strong>Market Opportunity:<\/strong> Estimated 25,000+ eligible patients annually in China alone<\/li>\n\n\n\n<li><strong>Therapeutic Gap:<\/strong> High unmet need for targeted therapies with improved efficacy and safety<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-trial-design-amp-strategic-implications\" class=\"wp-block-heading\">Trial Design &amp; Strategic Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-free survival (PFS)<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Overall survival (OS), objective response rate (ORR), safety<\/td><\/tr><tr><td><strong>Sample Size<\/strong><\/td><td>Approximately 300-350 patients<\/td><\/tr><tr><td><strong>Study Duration<\/strong><\/td><td>Expected completion 2028<\/td><\/tr><tr><td><strong>Regulatory Pathway<\/strong><\/td><td>Potential priority review designation based on unmet medical need<\/td><\/tr><tr><td><strong>Commercial Strategy<\/strong><\/td><td>China-first approval with global expansion potential<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Dynamics:<\/strong> Rapidly growing segment with premium pricing and strong commercial performance<\/li>\n\n\n\n<li><strong>B7-H3 Target:<\/strong> Emerging target with multiple companies developing B7-H3-directed therapies<\/li>\n\n\n\n<li><strong>Differentiation Factors:<\/strong><\/li>\n\n\n\n<li>Reduced lymphocyte uptake design<\/li>\n\n\n\n<li>Topoisomerase I payload optimization<\/li>\n\n\n\n<li>Broad Phase I activity across tumor types<\/li>\n\n\n\n<li><strong>Gynecological Focus:<\/strong> Strategic concentration on high-need indication with clear regulatory pathway<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-pipeline-context-amp-corporate-strategy\" class=\"wp-block-heading\">Pipeline Context &amp; Corporate Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Oncology Portfolio:<\/strong> Represents CSPC&#8217;s advanced oncology development capabilities<\/li>\n\n\n\n<li><strong>ADC Platform:<\/strong> Builds on company&#8217;s expertise in targeted therapeutics<\/li>\n\n\n\n<li><strong>China Biopharma Leadership:<\/strong> Positions CSPC among leading Chinese pharmaceutical companies in innovative drug development<\/li>\n\n\n\n<li><strong>Global Ambitions:<\/strong> Successful Phase III could support international regulatory filings and partnership opportunities<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market acceptance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071601130_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026071601130_c.\"><\/object><a id=\"wp-block-file--media-b0d4f02d-ae6e-41a4-96ce-81dfd4dc80c8\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071601130_c.pdf\">2026071601130_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026071601130_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b0d4f02d-ae6e-41a4-96ce-81dfd4dc80c8\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,171,855],"class_list":["post-70195","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cspc-pharmaceutical","tag-hkg-1093"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator&#039;s choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70195\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator&#039;s choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70195\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-17T14:42:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-17T14:42:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70195#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70195\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer\",\"datePublished\":\"2026-07-17T14:42:45+00:00\",\"dateModified\":\"2026-07-17T14:42:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70195\"},\"wordCount\":473,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CSPC Pharmaceutical\",\"HKG: 1093\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70195#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70195\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70195\",\"name\":\"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-17T14:42:45+00:00\",\"dateModified\":\"2026-07-17T14:42:46+00:00\",\"description\":\"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator's choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70195#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70195\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator's choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70195","og_locale":"en_US","og_type":"article","og_title":"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer","og_description":"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator's choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.","og_url":"https:\/\/flcube.com\/?p=70195","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-17T14:42:45+00:00","article_modified_time":"2026-07-17T14:42:46+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70195#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70195"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer","datePublished":"2026-07-17T14:42:45+00:00","dateModified":"2026-07-17T14:42:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70195"},"wordCount":473,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","CSPC Pharmaceutical","HKG: 1093"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70195#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70195","url":"https:\/\/flcube.com\/?p=70195","name":"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-17T14:42:45+00:00","dateModified":"2026-07-17T14:42:46+00:00","description":"CSPC Pharmaceutical Group (HKG: 1093) announced the initiation of a randomized, multi-center, open-label Phase III clinical trial in China evaluating SYS 6043, a novel B7-H3-targeting antibody-drug conjugate (ADC), against investigator's choice of chemotherapy in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70195#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70195"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC Pharmaceutical Launches Phase III Trial of B7-H3-Targeting ADC SYS 6043 for Platinum-Resistant Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70195"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70195\/revisions"}],"predecessor-version":[{"id":70198,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70195\/revisions\/70198"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}